Value Proposition. No sensitizers to irradiation, androgen signaling inhibition, or chemotherapy for prostate cancer patients exist (apart from androgen signaling inhibitors themselves) - There are no companies that have the goal of making cancer therapeutics that target the non-vascular tumor microenvironment. - Having companion biomarkers for ENV105 provide the advantage of improved clinical success. Biomarkers provide an 18% advantage for phase 2 trials moving to phase 3 and 21% improvement in gaining an NDA for drugs in phase 3 trials. - ENV105 has a proven safety record in 4 independent clinical trials employed in single agent and combination therapy strategies. - Formulation and capacity to scale up ENV105 production is in hand (Lonza Group) - Partnership with Tracon Pharmaceuticals Inc. provide experience in therapeutic development.
Appears in 2 contracts
Sources: Exclusive Option Agreement (Kairos Pharma, LTD.), Exclusive Option Agreement (Kairos Pharma, LTD.)